Physiogenomic method for predicting metabolic and cardiovascular side effects of thiazolidinediones

A physiogenomics method for determining a human individual's protection from or risk for developing a body mass index increase associated with the use of a thiazolidinedione drug, comprising

• assaying genetic material from the human individual with Type 2 diabetes for the presence of a risk genetic marker and a protective genetic marker to produce a combinatorial genotype for the human individual, wherein the human individual with Type 2 diabetes is undergoing thiazolidinedione therapy or is an individual for whom thiazolidinedione therapy may be indicated,
• wherein the risk marker is rs903361 (ADORA1) (SEQ ID NO:
• 1) and the protective marker is rs6586179 (LIPA) (SEQ ID NO:
• 7);
• and
• determining the protection from or risk for developing a body mass index increase in the human individual in response to the use of a thiazolidinedione drug by comparing the combinatorial genotype for the human individual with a predictive model comprising phenotype and genotype data for a thiazolidinedione drug-treated population, wherein the phenotype data includes body mass index for the thiazolidinedione drug-treated population, and wherein the thiazolidinedione drug is used in the treatment of Type 2 diabetes,
• wherein a minor allele copy number at position 22 of SEQ ID NO:
• 1 is associated with a likelihood of a body mass index increase associated with the use of a thiazolidinedione drug in the human individual and
• the a minor allele copy number at position 22 of SEQ ID NO:
• 7 is associated with a likelihood of a body mass index decrease associated with the use of a thiazolidinedione drug in the human individual.